Professor Dr. Michael Strupp is a Professor of Neurology and Clinical Neurophysiology at the Department of Neurology and German Centre for Vertigo and Balance Disorders at the Ludwig Maximilians University Hospital in Munich, Germany, where he specializes in vestibular, ocular motor, cerebellar and movement disorders. He studied medicine at the Technical University of Aachen and the University of Rochester, N.Y. Since then, he has been a passionate clinician, seeing patients daily, which is his motivation and driving force in science.

Prof. Dr. Strupp's extensive research, which includes 478 papers listed on PubMed (h-index 98) and five books on vertigo, dizziness, and ocular motor disorders, is a testament to his deep understanding of the field. Throughout his career, he has designed and performed 15 investigator initiated clinical trials. He has received numerous clinical and scientific awards. His many significant scientific achievements include the introduction of the potassium channel blocker 4-aminopyridine for the treatment of downbeat nystagmus and episodic ataxia type 2. More recently he and his team applied the modified amino acid Acetyl-leucine in the treatment of ataxias, Niemann-Pick Type C (NPC) and GM2-gangliosidoses, rare lysosomal storage disorders. In addition, in a paper he senior-authored in Nature Communications (Sept 2024), acetyl-leucine was able to halt the progression of Parkinson's disease in the prodromal phases of the disease and improve disease imaging markers. He is also a Founding Scientist at IntraBio, a biopharmaceutical company that is a leader in the discovery and development of innovative drugs for rare neurodegenerative diseases with high unmet needs. On September 25, 2024, IntraBio announced that they received FDA approval for AQNEURSA, a well-tolerated drug for the treatment of NPC in adults and pediatric patients. Prof. Dr. Strupp and the IntraBio team believe AQNEURSA can potentially treat other neurodevelopmental disorders, including patients with CACNA1A mutations and are committed to addressing those indications in the future.

Michael Strupp has four children, is an avid exercise enthusiast, and particularly enjoys biking and playing the piano. We are honored to have him join our board.